Inovio Pharma (INO-Q) Analyst Research & Price Targets - The Globe and Mail

Earnings Estimates

	Current Qtr06/2026	Next Qtr09/2026	Fiscal Yr12/2026	Fiscal Yr12/2027
Average Estimate	$-0.28	$-0.25	$-0.97	$-0.41
Number of Estimates	3	3	3	3
High Estimate	$-0.23	$-0.24	$-0.84	$-0.03
Low Estimate	$-0.34	$-0.25	$-1.05	$-0.96
Prior Year	$-0.61	$-0.44	$-1.80	$-0.97
Growth Rate Est. (year over year)	+54.10%	+43.18%	+46.11%	+57.73%

Earnings History - Surprises*

	Qtr Ending03/2026	Qtr Ending12/2025	Qtr Ending09/2025	Qtr Ending06/2025
Reported	$-0.28	$0.31	$-0.44	$-0.61
Estimate	$-0.30	$-0.37	$-0.51	$-0.63
Difference	+0.02	+0.68	+0.07	+0.02
Surprise	+6.67%	+183.78%	+13.73%	+3.17%

* Earnings are based on GAAP income from continuing operations.

Average Analyst Ratings

4.00

3 Mths Ago6

4.00

2 Mths Ago6

4.00

1 Mth Ago6

4.00

Current6

Ratings Values:

Strong Buy5

Moderate Buy4

Hold3

Moderate Sell2

Strong Sell1

Ratings Breakdown

	3 Mths Ago	2 Mths Ago	1 Mth Ago	Current
# of Analysts:	6	6	6	6
	3	3	3	3
Holds	3	3	3	3

Key:

Strong Buy

Moderate Buy

Hold

Moderate Sell

Strong Sell

More from The Globe

Wednesday’s analyst upgrades and downgrades

number cruncher

Seven Canadian small-cap stocks with cheap valuations

Bullish on Freeport-McMoRan Inc.

Gildan shares sink 19 per cent on short seller report alleging inflated sales

The highest-yielding stocks on the TSX, plus risk data

The most oversold and overbought stocks on the TSX

Insider Report: Co-chair buys the dip investing over US$1-million in this beaten-down stock

Extreme weather is coming. Here’s a stock that can sail through it